Australia markets closed

Eagle Pharmaceuticals, Inc. (EGRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
33.64-0.45 (-1.32%)
As of 12:03PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 432.26M
Enterprise value 481.65M
Trailing P/E 20.25
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.45
Price/book (mrq)1.86
Enterprise value/revenue 1.62
Enterprise value/EBITDA 8.12

Trading information

Stock price history

Beta (5Y monthly) 0.85
52-week change 3-23.53%
S&P500 52-week change 3-7.13%
52-week high 353.78
52-week low 324.35
50-day moving average 332.28
200-day moving average 336.82

Share statistics

Avg vol (3-month) 3156.99k
Avg vol (10-day) 3129.95k
Shares outstanding 513.02M
Implied shares outstanding 6N/A
Float 811.41M
% held by insiders 112.24%
% held by institutions 189.99%
Shares short (12 Jan 2023) 4968.66k
Short ratio (12 Jan 2023) 45.57
Short % of float (12 Jan 2023) 413.92%
Short % of shares outstanding (12 Jan 2023) 47.44%
Shares short (prior month 14 Dec 2022) 4605.66k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 7.14%
Operating margin (ttm)32.86%

Management effectiveness

Return on assets (ttm)19.06%
Return on equity (ttm)10.20%

Income statement

Revenue (ttm)298.23M
Revenue per share (ttm)23.11
Quarterly revenue growth (yoy)65.40%
Gross profit (ttm)129.37M
EBITDA 105.45M
Net income avi to common (ttm)21.28M
Diluted EPS (ttm)1.62
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)15.38M
Total cash per share (mrq)1.18
Total debt (mrq)64.77M
Total debt/equity (mrq)27.95
Current ratio (mrq)1.52
Book value per share (mrq)17.81

Cash flow statement

Operating cash flow (ttm)21.23M
Levered free cash flow (ttm)34.05M